BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33949809)

  • 1. Conditional disease-free survival rates and their associated determinants in patients with epithelial ovarian cancer: A 15-year retrospective cohort study.
    Ebrahimi V; Khalafi-Nezhad A; Ahmadpour F; Jowkar Z
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1416. PubMed ID: 33949809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological Tumor Type is Associated with One-Year Cause-Specific Survival in Women with Stage III-IV Epithelial Ovarian Cancer: A Surveillance, Epidemiology, and End Results (SEER) Database Population Study, 2004-2014.
    Wu SG; Li FY; Lei J; Hua L; He ZY; Zhou J
    Med Sci Monit; 2020 Feb; 26():e920531. PubMed ID: 32008036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
    Okunade KS; Dawodu O; Adenekan M; Nwogu CM; Awofeso O; Ugwu AO; Salako O; John-Olabode S; Olowoselu OF; Anorlu RI
    Niger J Clin Pract; 2020 Aug; 23(8):1141-1147. PubMed ID: 32788493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
    Mackay HJ; Brady MF; Oza AM; Reuss A; Pujade-Lauraine E; Swart AM; Siddiqui N; Colombo N; Bookman MA; Pfisterer J; du Bois A;
    Int J Gynecol Cancer; 2010 Aug; 20(6):945-52. PubMed ID: 20683400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer.
    Son JH; Kong TW; Paek J; Song KH; Chang SJ; Ryu HS
    Int J Gynaecol Obstet; 2017 Dec; 139(3):352-357. PubMed ID: 28857180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
    De Nonneville A; Zemmour C; Frank S; Joly F; Ray-Coquard I; Costaz H; Classe JM; Floquet A; De la Motte Rouge T; Colombo PE; Sauterey B; Leblanc E; Pomel C; Marchal F; Barranger E; Savoye AM; Guillemet C; Petit T; Pautier P; Rouzier R; Gladieff L; Simon G; Courtinard C; Sabatier R
    Gynecol Oncol; 2021 Oct; 163(1):64-71. PubMed ID: 34294414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
    Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer.
    Lin YH; Wu CH; Fu HC; Chen YJ; Chen YY; Ou YC; Lin H
    Cancer Biomark; 2020; 28(3):285-292. PubMed ID: 32390605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer.
    Khalafi-Nezhad A; Ebrahimi V; Ahmadpour F; Momtahan M; Robati M; Saraf Z; Ramzi M; Jowkar Z; Ghaffari P
    Cancer Manag Res; 2020; 12():1447-1456. PubMed ID: 32161497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer.
    Elzakkers JCJ; van der Aa MA; van Altena AM; de Hullu JA; Harmsen MG
    Gynecol Oncol; 2019 Nov; 155(2):213-219. PubMed ID: 31477282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
    Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
    J Ovarian Res; 2018 Mar; 11(1):21. PubMed ID: 29506569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
    Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
    Yang HM; Lou G
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
    [No Abstract]   [Full Text] [Related]  

  • 18. Isolated lymph node recurrence in epithelial ovarian cancer: Recurrence with better prognosis?
    Delangle R; Rossard L; Cirier J; Delvallée J; Bendifallah S; Touboul C; Collinet P; Coutant C; Akladios C; Lavoué V; Bolze PA; Huchon C; Bricou A; Canlorbe G; Ballester M; Darai E; Body G; Ouldamer L;
    Eur J Obstet Gynecol Reprod Biol; 2020 Jun; 249():64-69. PubMed ID: 32381349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
    Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
    Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
    Manning-Geist BL; Chi DS; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; O'Cearbhaill RE; Abu-Rustum NR; Leitao MM
    Gynecol Oncol; 2021 Aug; 162(2):345-352. PubMed ID: 34045053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.